<!doctype html><html lang=en><head><meta charset=utf-8><meta name=description content="Introduction  ‡πÇ‡∏£‡∏Ñ‡∏Ç‡πâ‡∏≠‡∏ó‡∏µ‡πà chronic, progressive, autoimmune ‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏£‡∏Ñ‡∏ó‡∏µ‡πà symmetry ‡πÅ‡∏•‡∏∞‡∏°‡∏µ‡∏ú‡∏•‡∏ï‡πà‡∏≠ synovium ‡∏Ç‡∏≠‡∏á‡∏Ç‡πâ‡∏≠ ‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£ extra-articular involvement ‡∏´‡∏•‡∏≤‡∏Å‡∏´‡∏•‡∏≤‡∏¢ ^14dfb0  ‡∏ï‡∏≤: vasculitis skin: rheumatoid nodule   40-50% ‡∏û‡∏¥‡∏Å‡∏≤‡∏£‡πÉ‡∏ô 5 ‡∏õ‡∏µ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡∏£‡∏±‡∏Å‡∏©‡∏≤  Risk Factors  60% genetics  epigenetic modification susceptibility genes   40% non-genetic  Pathophysiology  ‡∏£‡∏∞‡∏¢‡∏∞‡πÅ‡∏£‡∏Å ‡πÜ (preclinical RA) ‡∏≠‡∏≤‡∏à‡πÄ‡∏Å‡∏¥‡∏î citrullination ‡∏´‡∏•‡∏±‡∏á‡∏à‡∏≤‡∏Å‡∏ô‡∏±‡πâ‡∏ô‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á autoantibody ‡πÅ‡∏•‡πâ‡∏ß infiltrate ‡πÄ‡∏Ç‡πâ‡∏≤‡πÑ‡∏õ‡πÉ‡∏ô‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì‡∏Ç‡πâ‡∏≠ (early RA)  autoantibodies ‡πÄ‡∏ä‡πà‡∏ô APCAs ‡πÅ‡∏•‡∏∞ RF   ‡∏à‡∏ô‡∏™‡∏∏‡∏î‡∏ó‡πâ‡∏≤‡∏¢ shape ‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô (established RA)  Staging  Synovitis synovial membrane ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡πÄ‡∏â‡∏¢ ‡πÜ Pannus ‡πÄ‡∏Å‡∏¥‡∏î pannus ‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏°‡∏±‡∏ô‡πÇ‡∏î‡∏ô attack / ‡∏ï‡∏±‡∏ß cartilage ‡∏™‡∏π‡∏ç‡πÄ‡∏™‡∏µ‡∏¢‡πÑ‡∏õ‡πÄ‡∏¢‡∏≠‡∏∞ ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏°‡∏±‡∏Å CC ‡∏°‡∏≤‡πÉ‡∏ô stage ‡∏ô‡∏µ‡πâ Fibrous ankylosis ‡∏ï‡∏±‡∏ß fibrous connective tissue invade ‡∏ï‡∏±‡∏ß‡∏ß synovial Bony ankylosis ‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å‡πÄ‡∏ä‡∏∑‡πà‡∏≠‡∏°‡∏Å‡∏±‡∏ô  Clinical Features  prolonged morning stiffness more than 30 mins ‡∏≠‡∏≤‡∏à‡∏à‡∏∞‡∏õ‡∏ß‡∏î ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà‡∏õ‡∏ß‡∏î‡∏Å‡πá‡πÑ‡∏î‡πâ !"><meta property="og:title" content><meta property="og:description" content="Introduction  ‡πÇ‡∏£‡∏Ñ‡∏Ç‡πâ‡∏≠‡∏ó‡∏µ‡πà chronic, progressive, autoimmune ‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏£‡∏Ñ‡∏ó‡∏µ‡πà symmetry ‡πÅ‡∏•‡∏∞‡∏°‡∏µ‡∏ú‡∏•‡∏ï‡πà‡∏≠ synovium ‡∏Ç‡∏≠‡∏á‡∏Ç‡πâ‡∏≠ ‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£ extra-articular involvement ‡∏´‡∏•‡∏≤‡∏Å‡∏´‡∏•‡∏≤‡∏¢ ^14dfb0  ‡∏ï‡∏≤: vasculitis skin: rheumatoid nodule   40-50% ‡∏û‡∏¥‡∏Å‡∏≤‡∏£‡πÉ‡∏ô 5 ‡∏õ‡∏µ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡∏£‡∏±‡∏Å‡∏©‡∏≤  Risk Factors  60% genetics  epigenetic modification susceptibility genes   40% non-genetic  Pathophysiology  ‡∏£‡∏∞‡∏¢‡∏∞‡πÅ‡∏£‡∏Å ‡πÜ (preclinical RA) ‡∏≠‡∏≤‡∏à‡πÄ‡∏Å‡∏¥‡∏î citrullination ‡∏´‡∏•‡∏±‡∏á‡∏à‡∏≤‡∏Å‡∏ô‡∏±‡πâ‡∏ô‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á autoantibody ‡πÅ‡∏•‡πâ‡∏ß infiltrate ‡πÄ‡∏Ç‡πâ‡∏≤‡πÑ‡∏õ‡πÉ‡∏ô‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì‡∏Ç‡πâ‡∏≠ (early RA)  autoantibodies ‡πÄ‡∏ä‡πà‡∏ô APCAs ‡πÅ‡∏•‡∏∞ RF   ‡∏à‡∏ô‡∏™‡∏∏‡∏î‡∏ó‡πâ‡∏≤‡∏¢ shape ‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô (established RA)  Staging  Synovitis synovial membrane ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡πÄ‡∏â‡∏¢ ‡πÜ Pannus ‡πÄ‡∏Å‡∏¥‡∏î pannus ‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏°‡∏±‡∏ô‡πÇ‡∏î‡∏ô attack / ‡∏ï‡∏±‡∏ß cartilage ‡∏™‡∏π‡∏ç‡πÄ‡∏™‡∏µ‡∏¢‡πÑ‡∏õ‡πÄ‡∏¢‡∏≠‡∏∞ ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏°‡∏±‡∏Å CC ‡∏°‡∏≤‡πÉ‡∏ô stage ‡∏ô‡∏µ‡πâ Fibrous ankylosis ‡∏ï‡∏±‡∏ß fibrous connective tissue invade ‡∏ï‡∏±‡∏ß‡∏ß synovial Bony ankylosis ‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å‡πÄ‡∏ä‡∏∑‡πà‡∏≠‡∏°‡∏Å‡∏±‡∏ô  Clinical Features  prolonged morning stiffness more than 30 mins ‡∏≠‡∏≤‡∏à‡∏à‡∏∞‡∏õ‡∏ß‡∏î ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà‡∏õ‡∏ß‡∏î‡∏Å‡πá‡πÑ‡∏î‡πâ !"><meta property="og:type" content="website"><meta property="og:image" content="https://akumaharit.github.io/quartz/icon.png"><meta property="og:url" content="https://akumaharit.github.io/quartz/notes/RA/"><meta property="og:width" content="200"><meta property="og:height" content="200"><meta name=twitter:card content="summary"><meta name=twitter:title content><meta name=twitter:description content="Introduction  ‡πÇ‡∏£‡∏Ñ‡∏Ç‡πâ‡∏≠‡∏ó‡∏µ‡πà chronic, progressive, autoimmune ‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏£‡∏Ñ‡∏ó‡∏µ‡πà symmetry ‡πÅ‡∏•‡∏∞‡∏°‡∏µ‡∏ú‡∏•‡∏ï‡πà‡∏≠ synovium ‡∏Ç‡∏≠‡∏á‡∏Ç‡πâ‡∏≠ ‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£ extra-articular involvement ‡∏´‡∏•‡∏≤‡∏Å‡∏´‡∏•‡∏≤‡∏¢ ^14dfb0  ‡∏ï‡∏≤: vasculitis skin: rheumatoid nodule   40-50% ‡∏û‡∏¥‡∏Å‡∏≤‡∏£‡πÉ‡∏ô 5 ‡∏õ‡∏µ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡∏£‡∏±‡∏Å‡∏©‡∏≤  Risk Factors  60% genetics  epigenetic modification susceptibility genes   40% non-genetic  Pathophysiology  ‡∏£‡∏∞‡∏¢‡∏∞‡πÅ‡∏£‡∏Å ‡πÜ (preclinical RA) ‡∏≠‡∏≤‡∏à‡πÄ‡∏Å‡∏¥‡∏î citrullination ‡∏´‡∏•‡∏±‡∏á‡∏à‡∏≤‡∏Å‡∏ô‡∏±‡πâ‡∏ô‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á autoantibody ‡πÅ‡∏•‡πâ‡∏ß infiltrate ‡πÄ‡∏Ç‡πâ‡∏≤‡πÑ‡∏õ‡πÉ‡∏ô‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì‡∏Ç‡πâ‡∏≠ (early RA)  autoantibodies ‡πÄ‡∏ä‡πà‡∏ô APCAs ‡πÅ‡∏•‡∏∞ RF   ‡∏à‡∏ô‡∏™‡∏∏‡∏î‡∏ó‡πâ‡∏≤‡∏¢ shape ‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô (established RA)  Staging  Synovitis synovial membrane ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡πÄ‡∏â‡∏¢ ‡πÜ Pannus ‡πÄ‡∏Å‡∏¥‡∏î pannus ‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏°‡∏±‡∏ô‡πÇ‡∏î‡∏ô attack / ‡∏ï‡∏±‡∏ß cartilage ‡∏™‡∏π‡∏ç‡πÄ‡∏™‡∏µ‡∏¢‡πÑ‡∏õ‡πÄ‡∏¢‡∏≠‡∏∞ ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏°‡∏±‡∏Å CC ‡∏°‡∏≤‡πÉ‡∏ô stage ‡∏ô‡∏µ‡πâ Fibrous ankylosis ‡∏ï‡∏±‡∏ß fibrous connective tissue invade ‡∏ï‡∏±‡∏ß‡∏ß synovial Bony ankylosis ‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å‡πÄ‡∏ä‡∏∑‡πà‡∏≠‡∏°‡∏Å‡∏±‡∏ô  Clinical Features  prolonged morning stiffness more than 30 mins ‡∏≠‡∏≤‡∏à‡∏à‡∏∞‡∏õ‡∏ß‡∏î ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà‡∏õ‡∏ß‡∏î‡∏Å‡πá‡πÑ‡∏î‡πâ !"><meta name=twitter:image content="https://akumaharit.github.io/quartz/icon.png"><title>ü™¥ Harit's External Brain</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://akumaharit.github.io/quartz//icon.png><link href=https://akumaharit.github.io/quartz/styles.b369a84b3c6e6bfd686ad1f9da65641c.min.css rel=stylesheet><link href=https://akumaharit.github.io/quartz/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://akumaharit.github.io/quartz/js/darkmode.a68a7442418d0a27fed8a6af6c0a0229.min.js></script>
<script src=https://akumaharit.github.io/quartz/js/util.a0ccf91e1937fe761a74da4946452710.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/npm/@floating-ui/core@1.2.1></script>
<script src=https://cdn.jsdelivr.net/npm/@floating-ui/dom@1.2.1></script>
<script async src=https://akumaharit.github.io/quartz/js/popover.aa9bc99c7c38d3ae9538f218f1416adb.min.js></script>
<script defer src=https://akumaharit.github.io/quartz/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://akumaharit.github.io/quartz/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://akumaharit.github.io/quartz/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://akumaharit.github.io/quartz/",fetchData=Promise.all([fetch("https://akumaharit.github.io/quartz/indices/linkIndex.bff4888056c9000936caf90dcafa7696.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://akumaharit.github.io/quartz/indices/contentIndex.243bc1e394a2819f73a9ee68cdf6fc6c.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://akumaharit.github.io/quartz",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://akumaharit.github.io/quartz",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}var i=document.getElementsByClassName("mermaid");i.length>0&&import("https://unpkg.com/mermaid@9/dist/mermaid.esm.min.mjs").then(e=>{e.default.init()});function a(n){const e=n.target,t=e.className.split(" "),s=t.includes("broken"),o=t.includes("internal-link");plausible("Link Click",{props:{href:e.href,broken:s,internal:o,graph:!1}})}const r=document.querySelectorAll("a");for(link of r)link.className.includes("root-title")&&link.addEventListener("click",a,{once:!0})},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'‚Äô':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/akumaharit.github.io\/quartz\/js\/router.d6fe6bd821db9ea97f9aeefae814d8e7.min.js"
    attachSPARouting(init, render)
  </script><script defer data-domain=akumaharit.github.io/quartz src=https://plausible.io/js/script.js></script>
<script>window.plausible=window.plausible||function(){(window.plausible.q=window.plausible.q||[]).push(arguments)}</script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=Search placeholder="Search for something..."><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://akumaharit.github.io/quartz/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a class=root-title href=https://akumaharit.github.io/quartz/>ü™¥ Harit's External Brain</a></h1><div class=spacer></div><div id=search-icon><p>Search</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">Search Icon</title><desc id="desc">Icon to open search</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>Light Mode</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>Dark Mode</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><p class=meta>Last updated
Mar 8, 2023</p><ul class=tags></ul><aside class=mainTOC><details><summary>Table of Contents</summary><nav id=TableOfContents><ol><li><ol><li><a href=#introduction>Introduction</a></li><li><a href=#risk-factors>Risk Factors</a></li><li><a href=#pathophysiology>Pathophysiology</a></li><li><a href=#staging>Staging</a></li><li><a href=#clinical-features>Clinical Features</a></li><li><a href=#diagnosis>Diagnosis</a></li><li><a href=#differential-diagnosis>Differential Diagnosis</a></li><li><a href=#diagnosis-criteria>Diagnosis Criteria</a></li><li><a href=#management>Management</a></li><li><a href=#monitoring>Monitoring</a></li><li><a href=#non-pharmacological-therapy>Non-pharmacological therapy</a></li><li><a href=#pharmacological-therapy>Pharmacological Therapy</a></li><li><a href=#guideline>Guideline</a></li></ol></li></ol></nav></details></aside><a href=#introduction><h3 id=introduction><span class=hanchor arialabel=Anchor># </span>Introduction</h3></a><ul><li>‡πÇ‡∏£‡∏Ñ‡∏Ç‡πâ‡∏≠‡∏ó‡∏µ‡πà chronic, progressive, autoimmune</li><li>‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏£‡∏Ñ‡∏ó‡∏µ‡πà symmetry ‡πÅ‡∏•‡∏∞‡∏°‡∏µ‡∏ú‡∏•‡∏ï‡πà‡∏≠ synovium ‡∏Ç‡∏≠‡∏á‡∏Ç‡πâ‡∏≠</li><li>‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£ extra-articular involvement ‡∏´‡∏•‡∏≤‡∏Å‡∏´‡∏•‡∏≤‡∏¢ ^14dfb0<ul><li>‡∏ï‡∏≤: vasculitis</li><li>skin: rheumatoid nodule</li></ul></li><li>40-50% ‡∏û‡∏¥‡∏Å‡∏≤‡∏£‡πÉ‡∏ô 5 ‡∏õ‡∏µ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡∏£‡∏±‡∏Å‡∏©‡∏≤</li></ul><a href=#risk-factors><h3 id=risk-factors><span class=hanchor arialabel=Anchor># </span>Risk Factors</h3></a><ul><li>60% genetics<ul><li>epigenetic modification</li><li>susceptibility genes</li></ul></li><li>40% non-genetic</li></ul><a href=#pathophysiology><h3 id=pathophysiology><span class=hanchor arialabel=Anchor># </span>Pathophysiology</h3></a><ul><li>‡∏£‡∏∞‡∏¢‡∏∞‡πÅ‡∏£‡∏Å ‡πÜ (preclinical RA) ‡∏≠‡∏≤‡∏à‡πÄ‡∏Å‡∏¥‡∏î citrullination</li><li>‡∏´‡∏•‡∏±‡∏á‡∏à‡∏≤‡∏Å‡∏ô‡∏±‡πâ‡∏ô‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á autoantibody ‡πÅ‡∏•‡πâ‡∏ß infiltrate ‡πÄ‡∏Ç‡πâ‡∏≤‡πÑ‡∏õ‡πÉ‡∏ô‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì‡∏Ç‡πâ‡∏≠ (early RA)<ul><li>autoantibodies ‡πÄ‡∏ä‡πà‡∏ô APCAs ‡πÅ‡∏•‡∏∞ RF</li></ul></li><li>‡∏à‡∏ô‡∏™‡∏∏‡∏î‡∏ó‡πâ‡∏≤‡∏¢ shape ‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô (established RA)</li></ul><a href=#staging><h3 id=staging><span class=hanchor arialabel=Anchor># </span>Staging</h3></a><ol><li>Synovitis synovial membrane ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡πÄ‡∏â‡∏¢ ‡πÜ</li><li>Pannus ‡πÄ‡∏Å‡∏¥‡∏î pannus ‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏°‡∏±‡∏ô‡πÇ‡∏î‡∏ô attack / ‡∏ï‡∏±‡∏ß cartilage ‡∏™‡∏π‡∏ç‡πÄ‡∏™‡∏µ‡∏¢‡πÑ‡∏õ‡πÄ‡∏¢‡∏≠‡∏∞ <strong>‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏°‡∏±‡∏Å CC ‡∏°‡∏≤‡πÉ‡∏ô stage ‡∏ô‡∏µ‡πâ</strong></li><li>Fibrous ankylosis ‡∏ï‡∏±‡∏ß fibrous connective tissue invade ‡∏ï‡∏±‡∏ß‡∏ß synovial</li><li>Bony ankylosis ‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å‡πÄ‡∏ä‡∏∑‡πà‡∏≠‡∏°‡∏Å‡∏±‡∏ô</li></ol><a href=#clinical-features><h3 id=clinical-features><span class=hanchor arialabel=Anchor># </span>Clinical Features</h3></a><ul><li>prolonged morning stiffness more than 30 mins</li><li><strong>‡∏≠‡∏≤‡∏à‡∏à‡∏∞‡∏õ‡∏ß‡∏î ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà‡∏õ‡∏ß‡∏î‡∏Å‡πá‡πÑ‡∏î‡πâ ! ‡∏ï‡πà‡∏≤‡∏á‡∏à‡∏≤‡∏Å <a href=/quartz/notes/OA rel=noopener class=internal-link data-src=/quartz/notes/OA>OA</a></strong></li><li>symptoms <strong>present for 6 weeks or more</strong></li><li>‡∏°‡∏±‡∏Å‡∏û‡∏ö‡∏ó‡∏µ‡πà‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì‡∏Ç‡πâ‡∏≠‡πÄ‡∏•‡πá‡∏Å ‡πÜ ‡πÑ‡∏°‡πà‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô OA ‡∏ó‡∏µ‡πà‡∏û‡∏ö‡πÄ‡∏à‡∏≠‡∏ó‡∏µ‡πà‡∏Ç‡πâ‡∏≠‡πÉ‡∏´‡∏ç‡πà</li><li>‡∏°‡∏±‡∏Å‡πÄ‡∏à‡∏≠‡∏ó‡∏µ‡πà‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì‡∏Ç‡πâ‡∏≠‡πÄ‡∏•‡πá‡∏Å ‡πÜ ‡πÅ‡∏•‡∏∞‡∏Ç‡πâ‡∏≠‡∏™‡πà‡∏ß‡∏ô‡∏õ‡∏•‡∏≤‡∏¢‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ <strong>‡∏¢‡∏Å‡πÄ‡∏ß‡πâ‡∏ô‡∏°‡∏∑‡∏≠</strong> ‡∏à‡∏∞‡πÄ‡∏à‡∏≠‡πÅ‡∏Ñ‡πà‡∏Ç‡πâ‡∏≠‡∏ï‡πâ‡∏ô ‡πÜ (MCP ‡πÅ‡∏•‡∏∞ PIP) ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤ OA ‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô PIP DIP<ul><li><a class="internal-link broken">375</a></li></ul></li><li>‡∏´‡∏≤‡∏Å‡∏Ç‡πâ‡∏≠ MCP PIP ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡πÄ‡∏Å‡∏¥‡∏ô 3 ‡∏õ‡∏µ ‡∏≠‡∏≤‡∏à‡∏à‡∏∞‡∏ñ‡∏π‡∏Å‡∏ó‡∏≥‡∏•‡∏≤‡∏¢‡πÅ‡∏•‡∏∞‡πÄ‡∏ä‡∏∑‡πà‡∏≠‡∏°‡∏Å‡∏±‡∏ô‡πÅ‡∏ö‡∏ö‡∏ñ‡∏≤‡∏ß‡∏£ ‡πÄ‡∏Å‡∏¥‡∏î‡πÄ‡∏õ‡πá‡∏ô Z-deformity, swan neck deformity, boutonni√®re deformity</li><li>‡∏≠‡∏≤‡∏à‡∏°‡∏µ <a href=/quartz#14dfb0 rel=noopener class=internal-link data-src=/quartz>‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ô‡∏≠‡∏Å‡∏Ç‡πâ‡∏≠</a><ul><li>generalized fatigue</li><li>rheumatoid nodule (‡∏ï‡∏£‡∏ß‡∏à)</li></ul></li></ul><a href=#diagnosis><h3 id=diagnosis><span class=hanchor arialabel=Anchor># </span>Diagnosis</h3></a><a href=#lab><h4 id=lab><span class=hanchor arialabel=Anchor># </span>Lab</h4></a><ul><li>CRP -> inflammatory marker (acute)</li><li>ESR -> inflammatory marker (chronic)</li></ul><blockquote><p>‡∏û‡∏ß‡∏Å CRP/ESR ‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏ñ‡∏∂‡∏á‡∏Å‡∏≤‡∏£‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ specific ‡∏ß‡πà‡∏≤‡πÄ‡∏Å‡∏¥‡∏î‡∏Ç‡∏∂‡πâ‡∏ô‡∏ó‡∏µ‡πà‡∏Ç‡πâ‡∏≠</p></blockquote><ul><li>RF -> diagnostic marker ‡∏û‡∏ö‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ 70-80%</li><li>APCA -> ‡∏Ñ‡∏•‡πâ‡∏≤‡∏¢ RF ‡πÅ‡∏ï‡πà‡∏à‡∏∞ specific ‡∏Å‡∏ß‡πà‡∏≤‡∏°‡∏≤‡∏Å ‡πÜ</li><li>SF analysis ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏°‡∏µ high white blood cell count ‡πÅ‡∏•‡∏∞‡πÑ‡∏°‡πà‡∏°‡∏µ crystal or infection -> <a href=/quartz/notes/Synovial-Analysis#09e8b5 rel=noopener class=internal-link data-src=/quartz/notes/Synovial-Analysis>Class 2</a></li></ul><a href=#x-ray><h4 id=x-ray><span class=hanchor arialabel=Anchor># </span>X-Ray</h4></a><ul><li>‡πÉ‡∏ä‡πâ x-ray ‡∏ò‡∏£‡∏£‡∏°‡∏î‡∏≤‡∏Å‡πá‡∏û‡∏≠‡πÅ‡∏•‡πâ‡∏ß</li><li>‡∏£‡∏∞‡∏¢‡∏∞‡πÅ‡∏£‡∏Å ‡πÜ ‡∏≠‡∏≤‡∏à‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô soft tissue swelling and joint space narrowing ‡πÅ‡∏ï‡πà‡∏£‡∏∞‡∏¢‡∏∞‡∏ó‡πâ‡∏≤‡∏¢ ‡πÜ ‡∏≠‡∏≤‡∏à‡πÄ‡∏£‡∏¥‡πà‡∏°‡πÄ‡∏´‡πâ‡∏ô joint subluxations, deviations, and secondary arthritis</li></ul><a href=#differential-diagnosis><h3 id=differential-diagnosis><span class=hanchor arialabel=Anchor># </span>Differential Diagnosis</h3></a><blockquote><p>‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏≠‡∏≤‡∏à‡πÄ‡∏õ‡πá‡∏ô overlap syndrome ‡πÑ‡∏î‡πâ (‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏•‡∏≤‡∏¢‡πÇ‡∏£‡∏Ñ‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ô)</p></blockquote><ul><li>OA</li><li>crystal-induced arthritis ‡πÄ‡∏Ç‡πà‡∏ô gout, pseudogout</li><li>systemic lupus erythematosus<ul><li>‡∏≠‡∏≤‡∏à Rf ‡∏ö‡∏ß‡∏Å ‡πÅ‡∏ï‡πà involve organ ‡∏≠‡∏∑‡πà‡∏ô‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤</li></ul></li><li>vasculitis</li><li>spondylarthritis ‡πÄ‡∏ä‡πà‡∏ô psoriatic arthritis<ul><li>Rf ‡∏•‡∏ö‡πÅ‡∏ï‡πà‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏à‡∏∞‡∏Ñ‡∏•‡πâ‡∏≤‡∏¢ RA ‡∏°‡∏≤‡∏Å ‡πÜ</li><li>‡∏ú‡∏•‡∏ü‡∏¥‡∏•‡πå‡∏°‡∏à‡∏∞‡πÄ‡∏´‡πá‡∏ô‡∏Ñ‡∏ß‡∏≤‡∏°‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥‡∏≠‡∏¢‡∏π‡πà‡∏ô‡∏∞ ‡∏ï‡πà‡∏≤‡∏á‡∏à‡∏≤‡∏Å <a href=/quartz/notes/SLE rel=noopener class=internal-link data-src=/quartz/notes/SLE>SLE</a></li></ul></li></ul><a href=#diagnosis-criteria><h3 id=diagnosis-criteria><span class=hanchor arialabel=Anchor># </span>Diagnosis Criteria</h3></a><ul><li>‡πÉ‡∏´‡πâ‡∏´‡∏°‡∏≠‡∏ó‡∏≥‡πÄ‡∏ñ‡∏≠‡∏∞ ‡∏°‡∏µ‡πÄ‡∏Å‡∏ì‡∏ë‡πå‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏ï‡∏≤‡∏° guideline</li></ul><a href=#management><h3 id=management><span class=hanchor arialabel=Anchor># </span>Management</h3></a><blockquote><p>‡∏•‡∏î inflammation! ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏™‡∏ô‡πÄ‡∏£‡∏∑‡πà‡∏≠‡∏á‡∏õ‡∏ß‡∏î‡πÑ‡∏°‡πà‡∏õ‡∏ß‡∏î
joint damage ‡∏ó‡∏µ‡πà‡πÄ‡∏Å‡∏¥‡∏î‡∏Ç‡∏∂‡πâ‡∏ô‡πÅ‡∏•‡πâ‡∏ß‡∏à‡∏∞‡πÑ‡∏°‡πà reverse ‡∏Å‡∏•‡∏±‡∏ö‡∏Ñ‡∏∑‡∏ô‡∏°‡∏≤‡∏õ‡∏Å‡∏ï‡∏¥</p></blockquote><a href=#monitoring><h3 id=monitoring><span class=hanchor arialabel=Anchor># </span>Monitoring</h3></a><blockquote><p>‡∏ñ‡πâ‡∏≤‡πÄ‡∏Å‡∏¥‡∏î‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÉ‡∏ä‡πâ‡∏Ñ‡∏∞‡πÅ‡∏ô‡∏ô‡∏≠‡∏∞‡πÑ‡∏£‡∏û‡∏ß‡∏Å‡∏ô‡∏µ‡πâ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏°‡∏≤‡πÅ‡∏ï‡πà‡πÅ‡∏£‡∏Å ‡∏Å‡πá‡πÑ‡∏°‡πà‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡πâ‡∏≠‡∏á‡πÉ‡∏ä‡πâ ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡πÉ‡∏ä‡πâ‡πÅ‡∏•‡πâ‡∏ß‡∏Å‡πá‡πÉ‡∏ä‡πâ‡πÑ‡∏õ‡∏ï‡∏•‡∏≠‡∏î ‡∏õ‡∏Å‡∏ï‡∏¥‡πÅ‡∏•‡πâ‡∏ß DAS28 ‡∏Å‡∏±‡∏ö SDAI ‡∏à‡∏∞‡∏ô‡∏¥‡∏¢‡∏°‡πÉ‡∏ä‡πâ‡∏ï‡∏¥‡∏î‡∏ï‡∏≤‡∏° / monitor ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà‡∏Å‡πá‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏á‡∏≤‡∏ô‡∏ß‡∏¥‡∏à‡∏±‡∏¢</p></blockquote><ul><li><a class="internal-link broken">Disease Activity</a><ul><li>‡∏à‡∏∞‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡πÅ‡∏ö‡πà‡∏á‡πÄ‡∏õ‡πá‡∏ô ‡πÇ‡∏£‡∏Ñ‡∏™‡∏á‡∏ö ‡∏†‡∏≤‡∏ß‡∏∞‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏ô‡πâ‡∏≠‡∏¢ ‡∏†‡∏≤‡∏ß‡∏∞‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏õ‡∏≤‡∏ô‡∏Å‡∏•‡∏≤‡∏á ‡∏†‡∏≤‡∏ß‡∏∞‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏°‡∏≤‡∏Å</li><li>‡πÄ‡∏õ‡πâ‡∏≤‡∏´‡∏°‡∏≤‡∏¢ ‚Üí ‡πÉ‡∏´‡πâ‡πÇ‡∏£‡∏Ñ‡πÄ‡∏Ç‡πâ‡∏≤‡∏™‡∏π‡πà‡∏£‡∏∞‡∏¢‡∏∞‡∏™‡∏á‡∏ö</li><li>ACR/EULAR ‡πÇ‡∏£‡∏Ñ‡∏™‡∏á‡∏ö‡∏´‡∏°‡∏≤‡∏¢‡∏ñ‡∏∂‡∏á‡∏à‡∏≥‡∏ô‡∏ß‡∏ô‡∏Ç‡πâ‡∏≠‡∏ö‡∏ß‡∏° ‚â§ 1 ‡∏Ç‡πâ‡∏≠ ‡∏´‡∏£‡∏∑‡∏≠ SDAI &lt; 3.3</li><li>DAS28<ul><li>‡∏ô‡πâ‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤ 2.6 ‡∏™‡∏á‡∏ö</li><li>2.6-3.2 ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏ô‡πâ‡∏≠‡∏¢</li><li>3.2-5.1 ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏õ‡∏≤‡∏ô‡∏Å‡∏•‡∏≤‡∏á</li><li>‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ 5.1 ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏°‡∏≤‡∏Å</li></ul></li></ul></li><li>poor prognostic factors<ul><li>‡∏Å‡∏≤‡∏£‡∏°‡∏µ RF and/or APCA high levels</li><li>high disease activity</li><li>early joint damage</li><li>failure of >= 2 csDMARDs</li></ul></li><li>‡∏≠‡∏≤‡∏à‡∏°‡∏µ‡πÉ‡∏ä‡πâ‡∏û‡∏ß‡∏Å ACR20 ACR50 ACR70 ‡πÑ‡∏ß‡πâ‡∏î‡∏π improvement ‡∏ß‡πà‡∏≤‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô‡πÅ‡∏Ñ‡πà‡πÑ‡∏´‡∏ô</li></ul><a href=#non-pharmacological-therapy><h3 id=non-pharmacological-therapy><span class=hanchor arialabel=Anchor># </span>Non-pharmacological therapy</h3></a><ul><li>patient education</li><li>rest</li><li>holistic health</li><li>surgery last resort ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏Å‡∏•‡∏±‡∏ö‡∏°‡∏≤ 100% ‡∏ô‡∏∞!</li><li>physical therapy, occupation therapy</li><li>weight reduction ‡∏ä‡πà‡∏ß‡∏¢‡∏•‡∏î‡∏†‡∏≤‡∏£‡∏∞‡∏Ç‡πâ‡∏≠‡πÑ‡∏î‡πâ</li></ul><a href=#pharmacological-therapy><h3 id=pharmacological-therapy><span class=hanchor arialabel=Anchor># </span>Pharmacological Therapy</h3></a><ul><li>NSAIDs<ul><li>efficacy ‡πÑ‡∏°‡πà‡∏ï‡πà‡∏≤‡∏á‡∏Å‡∏±‡∏ô ‡πÑ‡∏°‡πà‡∏ß‡πà‡∏≤‡∏à‡∏∞ non-selective or selective ‡πÅ‡∏ï‡πà <strong>safety</strong> ‡∏°‡∏µ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÅ‡∏ï‡∏Å‡∏ï‡πà‡∏≤‡∏á‡∏Å‡∏±‡∏ô</li><li>‡πÉ‡∏ä‡πâ‡πÇ‡∏î‡∏™‡πÉ‡∏´‡πâ‡∏ñ‡∏∂‡∏á ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏•‡∏î inflammation <strong>‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πà‡πÇ‡∏î‡∏™‡∏•‡∏î‡∏õ‡∏ß‡∏î‡∏ò‡∏£‡∏£‡∏°‡∏î‡∏≤</strong></li></ul></li><li>Corticosteroids<ul><li>‡πÉ‡∏ä‡πâ‡∏Ç‡∏ô‡∏≤‡∏î‡∏ï‡πà‡∏≥ ‡πÄ‡∏ä‡πà‡∏ô 0.5 mkday (‡∏Ç‡∏ô‡∏≤‡∏î‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏ï‡πâ‡∏ô‡∏Ñ‡∏∑‡∏≠ 7.5 mg/day) ‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ö DMARDs ‡∏´‡∏£‡∏∑‡∏≠ NSAIDs ‡∏Å‡πá‡πÑ‡∏î‡πâ ‡πÅ‡∏•‡πâ‡∏ß‡πÅ‡∏ï‡πà‡∏ß‡πà‡∏≤‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏ô‡∏±‡∏Å‡πÄ‡∏ö‡∏≤‡πÅ‡∏Ñ‡πà‡πÑ‡∏´‡∏ô ‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡∏ß‡πà‡∏≤‡∏≠‡∏±‡∏ô‡πÑ‡∏´‡∏ô‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤‡∏Å‡∏±‡∏ô</li><li>steroid ‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡πÄ‡∏°‡∏∑‡πà‡∏≠ ‡∏°‡∏µ‡∏Ç‡πâ‡∏≠‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á‡∏à‡∏ô‡∏Å‡∏£‡∏∞‡∏ó‡∏ö‡∏ä‡∏µ‡∏ß‡∏¥‡∏ï‡∏õ‡∏£‡∏∞‡∏à‡∏≥‡∏ß‡∏±‡∏ô ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà‡∏ï‡∏≠‡∏ö‡∏™‡∏ô‡∏≠‡∏á‡∏ï‡πà‡∏≠ NSAIDs ‡∏´‡∏£‡∏∑‡∏≠‡πÉ‡∏ä‡πâ NSAIDs ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ</li><li><strong>‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤‡∏†‡∏≤‡∏¢‡πÉ‡∏ô 3-6 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô (ideally)</strong></li></ul></li><li>Tramadol<ul><li>‡∏Å‡∏£‡∏ì‡∏µ‡∏ó‡∏µ‡πà‡∏õ‡∏ß‡∏î‡∏´‡∏ô‡∏±‡∏Å‡∏°‡∏≤‡∏Å ‡πÜ ‡∏à‡∏£‡∏¥‡∏á ‡πÜ</li></ul></li><li>DMARDs<ul><li>Synthetic<ul><li>Conventional<ul><li>HCQ/CQ <strong>(non-immunosupressive)</strong><ul><li>200-400 mg/day</li><li>‡∏ï‡∏£‡∏ß‡∏à‡∏ï‡∏≤‡∏Å‡πà‡∏≠‡∏ô ‡∏ï‡∏£‡∏ß‡∏à fundus</li><li>‡∏õ‡∏ß‡∏î‡∏´‡∏±‡∏ß N/V</li><li>irreversible retinal damage</li><li>skin pigmentation</li><li>‡πÉ‡∏ä‡πâ‡∏Å‡∏±‡∏ö constitutional symptoms ‡πÑ‡∏î‡πâ ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ä‡πà‡∏ß‡∏¢‡∏•‡∏î joint damage progression</li></ul></li><li>Sulfasalazine <strong>(non-immunosupressive)</strong><ul><li>enteric coated</li><li>‡∏ï‡∏±‡∏ß‡∏°‡∏±‡∏ô‡πÄ‡∏õ‡πá‡∏ô NSAIDs ‡πÅ‡∏•‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡∏¢‡∏≤‡∏Å‡∏•‡∏∏‡πà‡∏° sulfa</li><li>‡∏ï‡∏±‡∏ß CBC ‡∏î‡πâ‡∏ß‡∏¢ ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏Å‡∏î‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡∏Ç‡∏≠‡∏á‡πÑ‡∏Ç‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å‡πÑ‡∏î‡πâ‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô MTX (myelosuppression) ‡∏ï‡∏≤‡∏°‡∏à‡∏£‡∏¥‡∏á‡∏≠‡∏≤‡∏à‡∏ï‡πâ‡∏≠‡∏á‡πÉ‡∏™‡πà folic ‡πÅ‡∏ï‡πà‡∏°‡∏±‡∏ô‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÄ‡∏î‡πà‡∏ô‡πÄ‡∏ó‡πà‡∏≤ MTX</li></ul></li><li>Methotrexate<ul><li>hep tox</li><li>interstitial pneumonitis</li><li>‡∏ï‡∏£‡∏ß‡∏à‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡∏Ç‡∏≠‡∏á‡∏õ‡∏≠‡∏î‡∏Å‡πà‡∏≠‡∏ô‡πÉ‡∏ä‡πâ ‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥‡∏Å‡πá‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ</li><li>‡∏ï‡∏£‡∏ß‡∏à viral hepatitis ‡∏Å‡πà‡∏≠‡∏ô‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏¢‡∏≤</li><li>‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏° folic acid</li><li>‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤‡∏Å‡πà‡∏≠‡∏ô‡∏ó‡πâ‡∏≠‡∏á 3 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô<ul><li>‡∏ñ‡πâ‡∏≤‡πÉ‡∏ä‡πâ‡πÇ‡∏î‡∏™‡∏™‡∏π‡∏á (‡πÄ‡∏ä‡πà‡∏ô 15, 20, 25mg) ‡πÉ‡∏´‡πâ‡∏™‡∏•‡∏±‡∏ö‡πÑ‡∏õ SC ‡πÄ‡∏û‡∏£‡∏≤‡∏∞ F oral ‡πÑ‡∏°‡πà‡∏î‡∏µ ‡πÅ‡∏•‡∏∞‡πÇ‡∏î‡∏™‡πÄ‡∏î‡∏¥‡∏°‡∏Ç‡∏≠‡∏á oral ‡∏ñ‡πâ‡∏≤‡πÉ‡∏ä‡πâ‡∏Å‡∏±‡∏ö SC ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡πÉ‡∏´‡πâ‡∏ú‡∏•‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏ó‡∏µ‡πà‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤</li></ul></li></ul></li><li>Leflunomide<ul><li>diarrhea ‡πÄ‡∏î‡πà‡∏ô</li><li>‡∏ï‡∏£‡∏ß‡∏à viral hepatitis ‡∏Å‡πà‡∏≠‡∏ô‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏¢‡∏≤</li></ul></li><li>Azathioprine</li><li>Minocycline <strong>(non-immunosupressive)</strong></li><li>Cyclosporin A (CsA)<ul><li>‡πÄ‡∏õ‡πá‡∏ô calcineurin inhibitor</li><li>‡∏ï‡∏£‡∏ß‡∏à‡∏ï‡∏±‡∏ö ‡πÑ‡∏ï ‡πÄ‡∏•‡∏∑‡∏≠‡∏î</li><li>‡∏°‡∏±‡∏ô‡∏à‡∏∞‡πÄ‡∏û‡∏¥‡πà‡∏° photosensitivity ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏â‡∏≤‡∏¢‡∏£‡∏±‡∏á‡∏™‡∏µ‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß</li><li>high BP ‡πÅ‡∏•‡∏∞ gingival hyperplasia ‡πÑ‡∏î‡πâ</li></ul></li></ul></li><li>Targeted <strong>(‡πÉ‡∏´‡∏°‡πà‡∏™‡∏∏‡∏î)</strong><ul><li>Janus kinase (JAK inhibitor) ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πà‡∏¢‡∏≤ biologics !<ul><li>‡πÉ‡∏´‡πâ‡∏ï‡∏£‡∏ß‡∏à lipid profile, ‡πÅ‡∏•‡∏∞‡∏´‡πâ‡∏≤‡∏°‡πÄ‡∏£‡∏¥‡πà‡∏°‡πÉ‡∏ä‡πâ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å ANc &lt; 1000 ‡∏´‡∏£‡∏∑‡∏≠ Hb &lt; 9 gbdl</li><li>‡∏ï‡∏£‡∏ß‡∏à lipid profile ‡∏´‡∏•‡∏±‡∏á‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏¢‡∏≤ 3 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô</li><li>‡πÄ‡∏û‡∏¥‡πà‡∏° risk infection, blood clot ‡πÅ‡∏•‡∏∞ lipids (dose dependent)</li><li><strong>Tofacitinib</strong><ul><li>CYP3A4 ‡πÅ‡∏•‡∏∞ CYP2C19 !!!</li></ul></li><li>Baricitinib</li></ul></li></ul></li></ul></li><li>Biological<ul><li><strong>‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ó‡∏µ‡πà‡∏°‡∏µ infection ‡πÅ‡∏•‡∏∞‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ live vaccine ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡πÉ‡∏´‡πâ biological !!!</strong></li><li>Conventional<ul><li>TNF-alpha inhibitor ‡πÄ‡∏õ‡πâ‡∏ô‡∏¢‡∏≤ biological ‡∏ï‡∏±‡∏ß‡πÅ‡∏£‡∏Å ‡πÅ‡∏ï‡πà‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà‡πÄ‡∏õ‡πá‡∏ô SLE, lupus overlap syndrome, CHF</li><li>CD80 and CD86 inhibitor<ul><li>Abatacept</li></ul></li><li>anti PD20<ul><li>Rituximab -> ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡πÅ‡∏û‡πâ ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡πÉ‡∏´‡πâ methyprednisolone ‡∏Å‡πà‡∏≠‡∏ô‡πÉ‡∏ä‡πâ‡∏¢‡∏≤ ‡∏´‡∏£‡∏∑‡∏≠ paracetamol+hypersens</li></ul></li><li>IL-6R inhibitor<ul><li>Tocilizumab -> ‡πÄ‡∏û‡∏¥‡πà‡∏° liver transminases</li></ul></li><li>IL-1 inhibitor ‡∏°‡∏µ‡∏°‡∏≤‡∏ô‡∏≤‡∏ô‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà effective</li></ul></li><li>Biosimilar</li></ul></li></ul></li></ul><a href=#guideline><h3 id=guideline><span class=hanchor arialabel=Anchor># </span>Guideline</h3></a><ul><li>start DMARDs ASAP ‡∏´‡∏•‡∏±‡∏á‡∏ß‡∏¥‡∏ô‡∏¥‡∏à‡∏â‡∏±‡∏¢</li><li>goal: low disease activity or sustained remission</li><li>monitor ‡∏ñ‡∏µ‡πà‡πÉ‡∏ô‡∏ä‡πà‡∏ß‡∏á‡πÅ‡∏£‡∏Å q 1-3 mo. ‡∏´‡∏≤‡∏Å‡πÑ‡∏°‡πà‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô‡πÉ‡∏ô 3-6 mo. ‡πÉ‡∏´‡πâ adjust therapy<ul><li>‡∏´‡∏≤‡∏Å‡πÉ‡∏ä‡πâ csDMARD ‡∏Ñ‡∏£‡∏ö 2 ‡∏ï‡∏±‡∏ß‡πÑ‡∏°‡πà‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô ‡∏´‡∏£‡∏∑‡∏≠ poor prognostic factor ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ‡∏ï‡∏±‡∏ß bDMARD ‡πÅ‡∏ï‡πà‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ JAK-inhibitor ‡πÑ‡∏î‡πâ ‡πÅ‡∏ï‡πà‡∏ï‡πâ‡∏≠‡∏á‡∏î‡∏π risk factor ‡∏î‡πâ‡∏ß‡∏¢‡∏ß‡πà‡∏≤‡∏°‡∏µ‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡∏î‡∏±‡∏á‡∏ï‡πà‡∏≠‡πÑ‡∏õ‡∏ô‡∏µ‡πâ‡∏°‡∏±‡πâ‡∏¢: ‡∏≠‡∏≤‡∏¢‡∏∏‡πÄ‡∏Å‡∏¥‡∏ô 65 ‡∏õ‡∏µ, past smoking, CV risk factors, risk of malignancy, risk of thromboembolic events</li><li>‡∏à‡∏∞‡∏™‡∏•‡∏±‡∏ö ‡∏´‡∏£‡∏∑‡∏≠ add bDMARD/tsDMARD ‡∏Å‡πá‡πÑ‡∏î‡πâ ‡πÅ‡∏ï‡πà‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥‡πÉ‡∏´‡πâ add ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤‡∏™‡∏•‡∏±‡∏ö</li><li>IL-6 inhibitor (Tocilizumab) ‡πÄ‡∏õ‡πá‡∏ô bDMARDs ‡∏ó‡∏µ‡πà‡∏≠‡∏≤‡∏à‡∏°‡∏µ efficacy ‡πÄ‡∏¢‡∏≠‡∏∞‡∏Å‡∏ß‡πà‡∏≤‡∏ñ‡πâ‡∏≤‡∏ô‡∏≥‡πÑ‡∏õ‡πÉ‡∏ä‡πâ‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ö tsDMARDs</li><li><strong>‡∏´‡∏°‡∏≤‡∏¢‡πÄ‡∏´‡∏ï‡∏∏: ‡∏Ç‡∏≠‡∏á‡πÑ‡∏ó‡∏¢‡∏ö‡∏≠‡∏Å‡∏ß‡πà‡∏≤‡πÉ‡∏´‡πâ‡∏•‡∏≠‡∏á‡∏à‡∏ô‡∏Ñ‡∏£‡∏ö 3 ‡∏ï‡∏±‡∏ß ‡πÇ‡∏î‡∏¢‡∏ï‡∏±‡∏ß‡∏•‡∏∞ 2 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô ‡∏à‡∏∂‡∏á‡∏Ñ‡πà‡∏≠‡∏¢‡∏™‡∏•‡∏±‡∏ö‡πÄ‡∏õ‡πâ‡∏ô bDMARDs</strong></li></ul></li><li>‡∏ñ‡πâ‡∏≤‡∏à‡∏∞‡πÄ‡∏£‡∏¥‡πà‡∏° bDMARDs ‡πÉ‡∏´‡πâ‡∏´‡∏¢‡∏∏‡∏î GCs ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏Ñ‡∏π‡πà‡∏¢‡∏≤‡∏ô‡∏µ‡πâ‡πÑ‡∏°‡πà‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô ‡πÅ‡∏•‡∏∞‡∏¢‡∏±‡∏á‡πÄ‡∏û‡∏¥‡πà‡∏° AE ‡∏≠‡∏µ‡∏Å</li><li>‡∏ñ‡πâ‡∏≤‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏Ñ‡∏∏‡∏°‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡πÅ‡∏ï‡πà‡∏¢‡∏±‡∏á‡πÉ‡∏ä‡πâ GCs ‡∏≠‡∏¢‡∏π‡πà ‡πÅ‡∏™‡∏î‡∏á‡∏ß‡πà‡∏≤‡∏≠‡∏≤‡∏à‡πÑ‡∏°‡πà‡πÄ‡∏û‡∏µ‡∏¢‡∏á‡∏û‡∏≠ ‡πÉ‡∏´‡πâ‡∏õ‡∏£‡∏±‡∏ö‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏´‡∏•‡∏±‡∏Å‡∏´‡∏£‡∏∑‡∏≠‡∏û‡∏¢‡∏≤‡∏¢‡∏≤‡∏°‡∏´‡∏•‡∏∏‡∏î steroid</li><li>short-term GCs = 3 months, long-term = 3-6 months, chronic = more than 6 motnhs</li><li>MTX = first line ‡∏¢‡∏Å‡πÄ‡∏ß‡πâ‡∏ô‡∏°‡∏µ con</li><li>‡∏´‡∏≤‡∏Å‡πÄ‡∏Å‡∏¥‡∏î Flare ‡∏°‡∏±‡∏Å‡∏´‡∏°‡∏≤‡∏¢‡∏ñ‡∏∂‡∏á‡∏¢‡∏≤‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ‡∏Ñ‡∏∏‡∏°‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÑ‡∏°‡πà‡πÄ‡∏û‡∏µ‡∏¢‡∏á‡∏û‡∏≠</li><li>GCs ‡πÑ‡∏ß‡πâ‡πÉ‡∏ä‡πâ‡∏Å‡∏±‡∏ö ‡πÑ‡∏î‡πâ</li><li>JAK inhibitor and bDMARDs ‡πÑ‡∏°‡πà‡∏ï‡πà‡∏≤‡∏á‡∏Å‡∏±‡∏ô‡πÉ‡∏ô‡πÅ‡∏á‡πà safety/efficacy</li><li>contraindication ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ leflunomide or sulfasalazine</li><li>‡∏´‡∏•‡∏±‡∏á‡∏´‡∏¢‡∏∏‡∏î steroid ‡πÅ‡∏•‡πâ‡∏ß‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏Ñ‡∏∏‡∏°‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡∏î‡∏µ ‡∏≠‡∏≤‡∏à‡∏•‡∏î bDMARDs/tsDMARDs ‡πÅ‡∏•‡∏∞‡∏´‡∏£‡∏∑‡∏≠ csDMARDs</li><li><a class="internal-link broken">Pasted image 20230308124045.png</a></li></ul></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>Backlinks</h3><ul class=backlinks><li><a href=/quartz// data-ctx=notes/RA data-src=/ class=internal-link>ü™¥ Harit's External Brain</a></li><li><a href=/quartz/notes/SLE/ data-ctx=notes/RA data-src=/notes/SLE class=internal-link>SLE</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>Interactive Graph</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://akumaharit.github.io/quartz/js/graph.6579af7b10c818dbd2ca038702db0224.js></script></div></div><div id=contact_buttons><footer><p>Made by Harit Jeamvijit using <a href=https://github.com/jackyzha0/quartz>Quartz</a>, ¬© 2023</p><ul><li><a href=https://akumaharit.github.io/quartz/>Home</a></li><li><a href=https://github.com/akumaharit/>GitHub</a></li></ul></footer></div></div></body></html>